{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kocot J"],"funding":["Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH"],"pagination":["e183941"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12077908"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["135(10)"],"pubmed_abstract":["Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS. Clemastine fumarate, the over-the-counter antihistamine and muscarinic receptor blocker, has remyelinating potential in MS. A clemastine arm was added to an ongoing platform clinical trial, targeting residual activity by precision, biomarker-guided combination therapies of multiple sclerosis (TRAP-MS) (ClinicalTrials.gov NCT03109288), to identify a cerebrospinal fluid (CSF) remyelination signature and to collect safety data on clemastine in patients progressing independently of relapse activity (PIRA). The clemastine arm was stopped per protocol-defined criteria when 3 of 9 patients triggered individual safety stopping criteria. Clemastine-treated patients had significantly higher treatment-induced disability p"],"journal":["The Journal of clinical investigation"],"pubmed_title":["Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis."],"pmcid":["PMC12077908"],"funding_grant_id":["Division of Intramural Research,National Institute of Allergy","Infectious Diseases,NIH"],"pubmed_authors":["Peterson K","Ashida S","Kocot J","Pirjanian NA","Goldbach-Mansky R","Bielekova B","Fossati V","Holland SM","Kosa P"],"additional_accession":[]},"is_claimable":false,"name":"Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis.","description":"Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS. Clemastine fumarate, the over-the-counter antihistamine and muscarinic receptor blocker, has remyelinating potential in MS. A clemastine arm was added to an ongoing platform clinical trial, targeting residual activity by precision, biomarker-guided combination therapies of multiple sclerosis (TRAP-MS) (ClinicalTrials.gov NCT03109288), to identify a cerebrospinal fluid (CSF) remyelination signature and to collect safety data on clemastine in patients progressing independently of relapse activity (PIRA). The clemastine arm was stopped per protocol-defined criteria when 3 of 9 patients triggered individual safety stopping criteria. Clemastine-treated patients had significantly higher treatment-induced disability p","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T13:09:34.123Z","creation":"2026-04-18T03:11:21.784Z"},"accession":"S-EPMC12077908","cross_references":{"pubmed":["40371642"],"doi":["10.1172/JCI183941"]}}